Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid i in renal tissue from patients with aristolochic acid nephropathy

International Journal of Cancer

Volumn 135, Issue 2, 2014, Pages 502-507

  Schmeiser, Heinz H ^a   Nortier, Joëlle L ^b,c   Singh, Rajinder ^d   Gamboa Da Costa, Gonçalo ^e   Sennesael, Jacques ^f   Cassuto Viguier, Elisabeth ^g   Ambrosetti, Damien ^g   Rorive, Sandrine ^c   Pozdzik, Agnieszka ^c   Phillips, David H ^h   Stiborova, Marie ⁱ   Arlt, Volker M ^h  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^g PASTEUR HOSPITAL   (France)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

Author keywords

aristolochic acid; aristolochic acid nephropathy; biomarker of exposure; DNA adducts; persistence of adducts

Indexed keywords

7 (DEOXYADENOSIN N6 YL)ARISTOLACTAM I; ARISTOLOLACTAM; UNCLASSIFIED DRUG;

ADULT; AGED; ARISTOLOCHIC ACID NEPHROPATHY; ARTICLE; CARCINOGEN DNA INTERACTION; CLINICAL ARTICLE; DNA ADDUCT; DNA DETERMINATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; MALE; MASS SPECTROMETRY; MIDDLE AGED; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY; UROGENITAL TRACT CANCER;

ADULT; AGED; ARISTOLOCHIC ACIDS; BALKAN NEPHROPATHY; BIOLOGICAL MARKERS; CHROMATOGRAPHY, THIN LAYER; DNA ADDUCTS; FEMALE; HUMANS; KIDNEY; MALE; MASS SPECTROMETRY; MIDDLE AGED; MUTAGENS;

EID: 84900012261     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28681     Document Type: Article

References (24)

1. Arlt VM, Stiborova M, Schmeiser HH,. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002; 17: 265-77.
2. Grollman AP,. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen 2013; 54: 1-7.
3. Gokmen MR, Cosyns JP, Arlt VM, et al. The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med 2013; 158: 469-77.
4. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341: 387-91.
5. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342: 1686-92.
6. Lemy A, Wissing KM, Rorive S, et al. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis 2008; 51: 471-7.
7. Schmeiser HH, Bieler CA, Wiessler M, et al. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 1996; 56: 2025-8.
8. Bieler CA, Stiborova M, Wiessler M, et al. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 1997; 18: 1063-7.
9. Stiborova M, Martinek V, Frei E, et al. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer. Curr Drug Metab 2013; 14: 695-705.
10. Arlt VM, Alunni-Perret V, Quatrehomme G, et al. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int J Cancer 2004; 111: 977-80.
11. Schmeiser HH, Kucab JE, Arlt VM, Phillips DH, Hollstein M, Gluhovschi G, Gluhovschi C, Modilca M, Daminescu L, Petrica L, Velciov S,. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania. Environ Mol Mutagen 2012; 53: 636-41.
12. Chen CH, Dickman KG, Moriya M, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A 2012; 109: 8241-6.
13. Lord GM, Hollstein M, Arlt VM, et al. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 2004; 43: e11-7.
14. Schmeiser HH, Stiborova M, Arlt VM,. (32)P-postlabeling analysis of DNA adducts. Methods Mol Biol 2013; 1044: 389-401.
15. Chan W, Yue H, Poon WT, et al. Quantification of aristolochic acid-derived DNA adducts in rat kidney and liver by using liquid chromatography-electrospray ionization mass spectrometry. Mutat Res 2008; 646: 17-24.
16. Singh R, Arlt VM, Henderson CJ, et al. Detection and quantitation of N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine adducts in DNA using online column-switching liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 2155-62.
17. Fernando RC, Schmeiser HH, Scherf HR, et al. Formation and persistence of specific purine DNA adducts by 32P-postlabelling in target and non-target organs of rats treated with aristolochic acid I. IARC Sci Pub 1993;(23): 167-71.
18. Poirier MC, Reed E, Ozols RF, et al. DNA adducts of cisplatin in nucleated peripheral blood cells and tissues of cancer patients. Prog Exp Tumor Res 1987; 31: 104-13.
19. Ashurst SW, Cohen GM, Nesnow S, et al. Formation of benzo(a)pyrene/DNA adducts and their relationship to tumor initiation in mouse epidermis. Cancer Res 1983; 43: 1024-9.
20. Sidorenko VS, Yeo JE, Bonala RR, et al. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res 2012; 40: 2494-505.
21. Jelakovic B, Karanovic S, Vukovic-Lela I, et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 2012; 81: 559-67.
22. Poon SL, Pang ST, McPherson JR, et al. Genome-wide mutational signatures of aristolochic Acid and its application as a screening tool. Sci Transl Med 2013; 5: 197ra01.
23. Hoang ML, Chen CH, Sidorenko VS, et al. Mutational signature of aristolochic Acid exposure as revealed by whole-exome sequencing. Sci Transl Med 2013; 5: 197ra02.
24. Rappaport SM, Smith MT,. Epidemiology. Environment and disease risks. Science 2010; 330: 460-1.